AMRX · Amneal Pharmaceuticals, Inc.

The thesis

Amneal Pharmaceuticals' shift toward biosimilars, specialty drugs and complex generics passed its first test: third-quarter results on 3 November 2026 beat estimates and 2026 guidance rose again. The next report, around late February 2027, settles whether the lanreotide launch ramps and net debt falls as management promised.

Amneal now guides to 2026 revenue of $3.15–3.25 billion and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of $800–815 million, per its 3 November 2026 release. The new EBITDA floor sits above the old $780 million ceiling. The shares closed at $19.45 on 5 November 2026, below the $20.20 close on 21 October 2026 and 9.6% under the $21.51 52-week high in adjusted daily closes.

The narrative is maturing: JPMorgan and Leerink raised targets to $25 on 4 November 2026 and 5 November 2026, yet the shares sit below their level two weeks before the report. Crowding looks modest. The 14-day relative strength index (RSI) read 52.6 on 5 November 2026, the three-month gain was 8.8%, and the earnings date has passed. The visible supply question is the 28,942,098 Class A shares registered for resale by Kashiv sellers on 3 September 2026.

Bullish and bearish views on Amneal Pharmaceuticals, Inc.

The bull case on Amneal Pharmaceuticals, Inc. (AMRX), in brief: Results beat and guidance rose. The bear case: Debt rose with the Kashiv deal.

Bull case

• Results beat and guidance rose. Third-quarter revenue was $863 million, up 10% year over year, and adjusted EBITDA was $207 million, up 30%, per the 3 November 2026 release. Market reports put consensus at $816.058 million of revenue and $0.23 of adjusted earnings per share, against the $0.26 reported.
• Both growth segments accelerated. Affordable Medicines revenue rose 19% to $547 million on biosimilars, women's health patches and new launches, and Specialty rose 20% to $150 million, per the 3 November 2026 release. Second-quarter Specialty growth was 17%, per the 30 July 2026 release.
• Lanreotide starts small with room to grow. The chief financial officer put the third-quarter contribution at about $7 million and expects the fourth quarter to be "multiple times of that," per a transcript of the 3 November 2026 call. Management targets 30–40% market share over time, and Amneal's 18 September 2026 release cited $983 million of U.S. reference-product sales for the 12 months to July 2026.
• Kashiv removes profit sharing. Management cited $400–500 million of expected benefits from ending profit-sharing obligations and said Amneal now keeps all lanreotide profit, per the 3 November 2026 call. It also outlined a 2030 revenue target of $4.3–4.5 billion.
• Broker targets sit above the price. JPMorgan (Overweight) and Leerink (Outperform) moved to $25 on 4 November 2026 and 5 November 2026. Oppenheimer's $27 target dates from 23 September 2026.

Bear case

• Debt rose with the Kashiv deal. Gross debt was $3,231 million and net leverage 3.9 times at 30 September 2026, up from 3.5 times at the end of 2025, per the release. Contingent consideration liabilities add $383 million, and management expects to end 2026 at 3.6 times.
• Cash flow guidance fell as earnings guidance rose. The 2026 operating cash flow range dropped to $325–375 million from $350–400 million, per the release. Management attributed the change on the call to timing, citing an inventory build and collections moving into the first quarter of 2027.
• The Xolair biosimilar moved later. Management said on 3 November 2026 that the U.S. goal date is early 2027 and that launch would come late in the second half of 2027, under a patent settlement not yet struck. On the second-quarter call it had said a launch could come very late in 2026 or early 2027.
• Earnings quality and share count weigh. The third quarter showed a net loss under generally accepted accounting principles of $22 million, after $22 million of acquisition and integration costs and a higher tax provision. Diluted shares used for adjusted earnings per share rose to 348.4 million from 324.8 million a year earlier.
• AvKARE is shrinking for now. Revenue fell 17% to $165 million, which the company attributed to a non-recurring cardiovascular launch a year earlier. Management also cited a reset from deprioritizing a low-margin distribution channel.

Price setup

The close of $19.45 on 5 November 2026 sits just above $19.10, the prior high the shares cleared in September 2026. The 52-week high in adjusted daily closes moved to $21.51 from the $20.50 shown on 21 October 2026, so the shares set a new high and then gave it back within about two weeks. A second raise in four months has not lifted the shares above that earlier close of $20.20.

The RSI of 52.6 is neutral, and the three-month gain of 8.8% is smaller than the 12.7% shown on 21 October 2026. The gap to $19.10 is narrow, so an ordinary weekly decline could reach it. A weekly close back above $21.51 would show buyers accepting the raised guidance.

Catalysts, next 30 days

• ~30 November 2026, est.: Management said on the 3 November 2026 call that its omalizumab biosimilar has UK approval and a positive European Medicines Agency opinion, and that it expects final approval in late November. This tests regulatory execution on the product ahead of the U.S. decision.
• ~15 February 2027, est.: U.S. goal date for the omalizumab biosimilar, which management described only as "early next year." A patent settlement announcement would fix the launch date.
• ~26 February 2027, est.: Fourth-quarter and full-year 2026 report, with no date announced by Amneal. It shows the lanreotide ramp, year-end net leverage against the 3.6 times target, and any 2027 guidance.

What would change the view

A cut to the 3 November 2026 guidance of $3.15–3.25 billion in revenue or $800–815 million in adjusted EBITDA would break the operating case. So would year-end net leverage above management's 3.6 times, or fourth-quarter lanreotide revenue that fails to reach a clear multiple of the roughly $7 million reported for the third quarter.

A further cut to the $325–375 million operating cash flow range would undercut management's explanation that the October change was timing. A U.S. omalizumab launch moving beyond 2027, or a complete response letter from the Food and Drug Administration, would weaken the biosimilar part of the case.

On price, a weekly close below $19.10 would put the shares back under the September 2026 prior high and end the current reading.

What it trades with

The drivers in the 3 November 2026 report are company-specific: product launches, Kashiv integration and leverage. Teva is the most direct read-across, since management named it on the call as another omalizumab filer. Amneal's repricing amendments in February and August 2026 and its $3,231 million of gross debt tie its interest costs to credit conditions more closely than a lower-debt drug maker's. No measured correlation with the sector or the S&P 500 is cited here.